A2JMW6 Cytori Therapeutics Inc.

Cytori to Webcast Third Quarter Financial Results on November 14

Cytori to Webcast Third Quarter Financial Results on November 14

SAN DIEGO, Nov. 09, 2018 (GLOBE NEWSWIRE) -- Cytori Therapeutics, Inc. (NASDAQ: CYTX) will provide a live webcast of its third quarter financial results and business update on Wednesday, November 14, 2018 at 5:30 PM Eastern Time.

The dial-in information is as follows:

              Dial-In Number: +1.877.402.3914

              Conference ID: 9699923

Prior to the webcast at approximately 4:30 PM Eastern Time on November 14, Cytori will issue its third quarter earnings release which will review Cytori’s third quarter and year-to-date performance.  The webcast will be available both live and by replay two hours after the call in the “Webcasts” section of the company’s investor relations website.

About Cytori Therapeutics, Inc.

Cytori is developing, manufacturing, and commercializing nanoparticle-delivered oncology drugs and autologous adipose-derived regenerative cell (ADRC) therapies within its Nanomedicine™ and Cell Therapy™ franchises, respectively.  Cytori Nanomedicine™ is focused on the liposomal encapsulation of anti-neoplastic chemotherapy agents, which may enable the effective delivery of the agents to target sites while reducing systemic toxicity. The Cytori Nanomedicine™ product pipeline consists of ATI-0918 pegylated liposomal doxorubicin hydrochloride for breast cancer, ovarian cancer, multiple myeloma, and Kaposi’s sarcoma, a complex/hybrid generic drug, and ATI-1123 patented albumin-stabilized pegylated liposomal docetaxel for multiple solid tumors.  Cytori Cell Therapy™, prepared within several hours with the proprietary Celution® System and administered to the patient the same day, has been shown in preclinical and clinical studies to act principally by improving blood flow, modulating the immune system, and facilitating wound repair. As a result, Cytori Cell Therapy™ may provide benefits across multiple disease states and can be made available to the physician and patient at the point-of-care. For more information, visit .

Cytori Therapeutics, Inc.

Tiago Girao, 1.858.458.0900

EN
09/11/2018

Underlying

A2JMW6Cytori Therapeutics Inc.

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Cytori Therapeutics Inc.

 PRESS RELEASE
Free
A2JMW6 Cytori Therapeu...

Plus Therapeutics to Participate in Upcoming January Conferences

Plus Therapeutics to Participate in Upcoming January Conferences AUSTIN, Texas, Jan. 05, 2021 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: ) (the “Company”), a clinical-stage company focused on making a positive impact on patients’ lives, today announced that Marc Hedrick, M.D., President and Chief Executive Officer of Plus Therapeutics, will present at three upcoming virtual conferences. EventH.C. Wainwright BioConnect ConferenceDateJanuary 11-14, 2021TimePresentation available on demand January 11-14, 2021  EventBiotech Showcase 2021DateJanuary 11-15, 2021  EventICR Conference ...

January 5, 2021 1 EN
 PRESS RELEASE
Free
A2JMW6 Cytori Therapeu...

Plus Therapeutics Completes Sixth Dosing Cohort in ReSPECT™ Glioblasto...

Plus Therapeutics Completes Sixth Dosing Cohort in ReSPECT™ Glioblastoma Trial AUSTIN, Texas, Dec. 15, 2020 (GLOBE NEWSWIRE) -- (Nasdaq: ) (the “Company”), a clinical-stage pharmaceutical company developing novel, targeted and personalized therapies for rare and difficult to treat cancers, today announced completion of the sixth dosing cohort in the ReSPECT™ Phase 1 clinical trial evaluating the Company’s lead investigational asset, Rhenium NanoLiposome (RNL™), in patients with recurrent glioblastoma (GBM). The sixth cohort of the ReSPECT trial included an increase in both the RNL drug ...

December 15, 2020 1 EN
 PRESS RELEASE
Free
A2JMW6 Cytori Therapeu...

Plus Therapeutics to Present at 13th Annual LD Micro Main Event Confer...

Plus Therapeutics to Present at 13th Annual LD Micro Main Event Conference AUSTIN, Texas, Dec. 08, 2020 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: ) (the “Company”), a clinical-stage company focused on making a positive impact on patients’ lives, today announced that Marc Hedrick, M.D., President and Chief Executive Officer of Plus Therapeutics, has been invited to present a Company overview during the 13th Annual LD Micro Main Event Conference on Monday, December 14th at 10:40 a.m. ET. For conference participants, a live webcast of the presentation can be found by visiting the...

December 8, 2020 1 EN
 PRESS RELEASE
Free
A2JMW6 Cytori Therapeu...

Plus Therapeutics Expands ReSPECT™ Clinical Trial to MD Anderson Cance...

Plus Therapeutics Expands ReSPECT™ Clinical Trial to MD Anderson Cancer Center AUSTIN, Texas., Dec. 01, 2020 (GLOBE NEWSWIRE) -- (Nasdaq: ) (the “Company”), a clinical-stage pharmaceutical company developing novel, targeted and personalized therapies for rare and difficult to treat cancers, today announced that the University of Texas MD Anderson Cancer Center is now an active clinical trial site in its ongoing ReSPECT™ Phase 1 clinical trial, currently supported by the National Cancer Institute (NCI). ReSPECT is a multi-center, dose-finding study evaluating the Company’s lead investigat...

December 1, 2020 1 EN
 PRESS RELEASE
Free
A2JMW6 Cytori Therapeu...

Plus Therapeutics Announces Positive Interim Data from ReSPECT™ Phase ...

Plus Therapeutics Announces Positive Interim Data from ReSPECT™ Phase 1 Clinical Trial in Recurrent Glioblastoma Investigational drug RNL™ delivers up to fifteen times the absorbed dose of radiation compared to standard external beam radiation therapy RNL was generally well-tolerated with no dose-limiting toxicities observed Company management and principal investigator of ReSPECT to discuss interim data during webinar scheduled for Thursday, November 19, 2020 at 4:30 - 5:30 p.m. ET AUSTIN, Texas, Nov. 19, 2020 (GLOBE NEWSWIRE) -- (Nasdaq: ) (the “Company”), a clinical-stage pharmaceu...

November 19, 2020 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch